Skip to main content
Equibles
INSM logo

INSM · INSMED Inc

Track INSM — free

Use INSM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about INSM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$125.08 -5.58 (-4.27%) At close · Aug 20
Market Cap
$28.53B
Shares
218.38M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$125.08 Open$128.36 Day$124.60–130.27 52W close$91.88–211.41 Avg vol 30d2.8M Short int11.4M · 5.2% float · 5.1d Short vol25% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 2, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Buy Momentum Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg −13%
      below
      Price vs 50-day avg +14%
      above
      RSI (14) 58
      neutral
      MACD trend Positive
      52-week position 28%
      mid-range
      Momentum
      relative strength
      Weak
      1-month return +16%
      trailing
      6-month return −16%
      trailing
      YTD return −28%
      this year
      Relative strength −27%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $110 › 200d $144 — 200d above 50d
      Institutional flow Distributing
      -2% holders QoQ · +114 funds added
      Insider flow Distributing
      Net -$34.1M over 90 days · 100% sells
      Short interest Falling
      5.20% of float · ▼ -2.4% MoM · 5.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      666 holders — near 3-yr high, broad support
      Squeeze score 61
      elevated · 0–100
      Fundamentals
      Poor
      EPS growth −15%
      Y/Y
      Free cash flow $-967.6M
      Balance sheet $33.6M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 62%
      annualized · 1-yr
      Max drawdown −57%
      past year
      ATR 4.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 2
      Latest guidance · from the 8-K filed Aug 6, 2026
      full-year 2026
      BRINSUPRI revenues Initiated $1.25B – $1.4B
      ARIKAYCE revenues Initiated $450M – $470M
      peak
      Peak revenue estimate for TPIP at least $6B
      Peak revenue estimate for BRINSUPRI at least $7B
      Peak revenue estimate for ARIKAYCE at least $1B
      Prior guidance period ended · from the 8-K filed Oct 30, 2025
      Global ARIKAYCE revenue · full-year 2025 $420M – $430M
      ARIKAYCE revenue · Full-Year 2025 $420M – $430M
      Guided vs delivered · last 2 settled
      Full year 2024 global revenue full year 2024
      guided $340M – $360M
      $363.71M Beat +3.9%
      Full-year 2023 revenue full-year 2023
      guided $295M – $305M
      $305.21M Beat +1.7%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −13% Bearish
      Price vs 50-day avg
      +14% Bullish
      RSI (14)
      58 Neutral
      MACD trend
      Positive Bullish
      52-week position
      28% Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $110 › 200d $144 — 200d above 50d
      Institutional flow Distributing
      -2% holders QoQ · +114 funds added
      Insider flow Distributing
      Net -$34.1M over 90 days · 100% sells
      Short interest Falling
      5.20% of float · ▼ -2.4% MoM · 5.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      666 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $92 Now $125 · 28% Range high $211
      vs 200-day avg -13% vs 50-day avg +14%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Cash, cash equivalents, and marketable securities $1.2B as of June 30, 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      INSM
      INSMED Inc
      this stock
      		$28.53B -28.1% +66.7% — 5.2%
      ONC
      BeOne Medicines Ltd.
      		 $557.05B +21.5% +22179.2% 856.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $136.93B +19.2% +46.2% 31.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $86.39B +7.1% +20.8% 20.8 3.3%
      MRNA
      Moderna, Inc.
      		 $69.62B +352.1% +4.3% — 12.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      666
      % held
      106.1%
      Net QoQ
      +11.8M sh
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      735
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      11.4M
      Days to cover
      5.1d
      Change
      -274.2K sh
      View
      Short Volume
      Short vol %
      25%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1
      Value
      $103
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      42.0%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$34.1M
      Buyers / Sellers
      0 / 5
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Josh Gottheimer
      Amount
      $1.0K–$15.0K
      Traded
      Jun 10, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $606.4M
      Net income (FY)
      $-1.3B
      EPS diluted
      $-6.42
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $1.7M
      Shares
      10.7K
      Filed
      Apr 6, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      INSM -1.0% +16.5% -16.2% +26.9% -28.1%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY +1.0% +13.1% -27.4% +24.8% -40.0%
      Key facts CIK 1104506 CUSIP 457669307 13F (30d) 591 filings 583 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)